March 31, 2022
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results
FORT WORTH, TX, March 30, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc.…
Pharmaceuticals, Biotechnology and Life Sciences
FORT WORTH, TX, March 30, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc.…
Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs…
Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full…
BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in…
— Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases…
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million…
– Pipeline Includes Three New Chemical Entities with Clinical Proof-Of-Concept (POC) Following CRN04894 and CRN04777 Phase 1 Readouts in 2021…
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast…
Regulated information — Inside information March 29, 2022, 11:00 PM CETMarch 29, 2022, 5:00 PM ET Breda, the Netherlands —…
Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer…